Clinical Trial Detail

NCT ID NCT04150029
Title A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Azacitidine + Sabatolimab + Venetoclax

Age Groups: senior adult

No variant requirements are available.